Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9062869 | 0.92 | KLKB1 (0.40) | LOXL2CYP2D6CYP1A2CYP2C9TSHR | |
| SCHEMBL7788074 | 0.87 | TPSAB1 (0.49) | LOXL2CYP2D6CYP1A2CYP2C9TSHR | |
| SCHEMBL7787881 | 0.84 | LOXL2 (0.45) | LOXL2CYP2D6CYP1A2CYP2C9TSHR | |
| SCHEMBL8356748 | 0.83 | LOXL2 (0.46) | LOXL2CYP2D6CYP1A2CYP2C9TSHR | |
| SCHEMBL4646862 | 0.80 | IDO1 (0.49) | CYP2C19HDAC3HDAC4HDAC1HDAC7 | |
| 1400W SCHEMBL4467 | 0.79 | NOS1 (0.49) | LOXL2CYP2D6CYP1A2CYP2C9TSHR | |
| Bromide SCHEMBL11806748 | 0.79 | IDO1 (0.47) | CYP2C19HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL27479542 | 0.79 | LOXL2 (0.42) | LOXL2GLSPNMTENPP2MAPT | |
| Hydrochloric Acid SCHEMBL27495600 | 0.78 | SIGMAR1 (0.42) | LOXL2NOS1NOS2ALDH1A1NOS3 | |
| 1400W SCHEMBL3115594 | 0.78 | NOS1 (0.50) | LOXL2CYP2D6CYP1A2CYP2C9TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010034342-A1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | OPLINGER JEFFREY ALAN (US) | 2001-10-25 | — | — | US | disclosed |
| US-6297276-B1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | GLAXOSMITHKLINE | 2001-10-02 | — | — | US | disclosed |
| US-6225305-B1 | Substituted urea and isothiorea derivatives as no synthase inhibitors | GLAXO WELLCOME INC. | 2001-05-01 | — | — | US | disclosed |
| US-6090846-A | ADMINISTERING S-ETHYL-N-((4-TRIFLUOROMETHYL)PHENYL)ISOTHIOUREA | GLAXO WELLCOME INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0723438-A1 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-31 | — | — | EP | disclosed |
| WO-1995009619-A2 | SUBSTITUTED UREA AND ISOTHIOUREA DERIVATIVES AS NO SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034342-A1 | Substituted urea and isothiourea derivatives as no synthase inhibitors | NOS1, NOS2, SLC14A1 | LOXL2 4179/4885CYP2D6 1041/4885CYP1A2 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.